

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions and listings of claims in the application:

1-6. (Canceled)

27. (Currently Amended) The method of ~~claim 10~~ claim 43, wherein the host is a human.

38. (Currently Amended) The method of ~~claim 10~~ claim 43, wherein the pathogenic bacterial enterotoxins are produced by a *Shigella* spp.

9-42. (Canceled)

143. (Previously Presented) A method of attenuating the effect of pathogenic bacterial enterotoxins, comprising obtaining a pharmaceutical composition comprising a ~~diaminoalkyl compound~~ cadaverine and a pharmaceutical carrier, and administering to a host an amount of the pharmaceutical composition effective to attenuate the effect of pathogenic bacterial enterotoxins.

44. (Currently Amended) The method of ~~claim 10~~ claim 43, wherein the pathogenic bacterial enterotoxins are produced by one or more of *Shigella* spp., enteropathogenic *E. coli*, enterohemorrhagic *E. coli*, enterotoxigenic *E. coli*,

Application No.: 10/034,213  
Attorney Docket No.: 04995.0044-01

enteroaggregative *E. coli*, uropathogenic *E. coli*, meningitis-causing *E. coli* K-1, *Yersinia pestis*, *Yersinia pseudotuberculosis*, *Yersinia enterocolitica*, *Mycobacterium bovis*, *Listeria monocytogenes*, *Vibrio cholerae*, *Streptococcus pyogenes*, *Campylobacter jejuni*, or *Bacteroides fragilis*.

45-46. (Canceled)

5 ~~47~~ (Currently Amended) The method of ~~claim 10~~ <sup>1</sup> claim 43, wherein the pharmaceutical composition is also in an amount effective to attenuate transepithelial migration of polymorphonuclear leukocytes.